SABCS 2023 | Tertiary lymphoid structure and outcomes in early-stage HER2+ breast cancer

Saranya Chumsri, MD, Mayo Clinic, Jacksonville, FL, tells us about the N9831 (NCT00005970) trial which utilized integrated pathological quantification and genomic data to assess functional tertiary lymphoid structure (TLS) in association with MHC expression and outcomes in patients with HER2+ breast cancer treated with adjuvant trastuzumab. The study showed that a greater number of lymphoid aggregates (LA) was associated with improved outcomes in patients with early-stage HER2+ breast cancer. Additionally, patients with functional TLS with LA ≥ 1 and higher expression of BCL6 or IL21R had significantly improved outcomes when treated with trastuzumab. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) congress in San Antonio, TX

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.